{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T13:34:28Z","timestamp":1790861668721,"version":"4.1.0"},"reference-count":47,"publisher":"SAGE Publications","issue":"11","license":[{"start":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T00:00:00Z","timestamp":1777161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To evaluate the efficacy and safety of mepolizumab, a humanized monoclonal antibody that targets interleukin-5, a key mediator in eosinophilic inflammation, in reducing moderate-to-severe exacerbations among patients with eosinophilic chronic obstructive pulmonary disease (COPD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources:<\/jats:title>\n                    <jats:p>PubMed, Scopus, Web of Science, and Cochrane databases were systematically searched using the terms: \u201cMepolizumab,\u201d \u201cCOPD,\u201d \u201cChronic Obstructive Pulmonary Disease,\u201d for randomized controlled trials comparing subcutaneous mepolizumab (100 mg every 4 weeks) with placebo in patients with eosinophilic COPD from inception till July 2025.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection and Data Extraction:<\/jats:title>\n                    <jats:p>Randomized controlled trials comparing subcutaneous mepolizumab with placebo in adults with eosinophilic COPD were included. Two independent reviewers screened studies and extracted data. Finally, 4 studies with a total of 1953 patients were included. Of these, 978 (50.0%) received mepolizumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Synthesis:<\/jats:title>\n                    <jats:p>\n                      Statistical analysis was performed using R software (version 4.5.0). Mepolizumab significantly prolonged the time to first moderate or severe exacerbation (hazard ratio [HR] = 0.80; 95% confidence interval [CI] 0.69-0.92;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.016) and reduced the rate of moderate-to-severe exacerbations (rate ratio 0.80; 95% CI 0.78-0.83;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001). The risk of adverse events (AEs) (risk ratio [RR] = 1.00; 95% CI 0.95-1.06;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.962) was similar between groups, while the risk of serious adverse events or death (RR = 0.83; 95% CI 0.72-0.96;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.031) was significantly lower in the mepolizumab group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Relevance to Patient Care and Clinical Practice in Comparison With Existing Drugs:<\/jats:title>\n                    <jats:p>Mepolizumab provides a targeted, biomarker-guided treatment option, potentially reducing exacerbations without the added safety concerns like infections and metabolic complications as seen with existing therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion and Relevance:<\/jats:title>\n                    <jats:p>Mepolizumab reduces the time to first moderate or severe exacerbation and prolongs symptom-free periods in patients with eosinophilic COPD, without increasing the risk of AEs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280261437728","type":"journal-article","created":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T10:15:07Z","timestamp":1777198507000},"page":"1090-1102","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and Safety of Mepolizumab in Eosinophilic COPD: A Systematic Review and Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.1177","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-9937-3873","authenticated-orcid":false,"given":"Rahul","family":"Bisht","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Armed Forces Medical College, Pune, India"},{"name":"Department of Internal Medicine, Station Medicare Centre, Air Force Station Udhampur, Udhampur, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arusha","family":"Desai","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Armed Forces Medical College, Pune, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban Marcelo","family":"Mogrovejo Carri\u00f3n","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Universidad San Francisco de Quito, Quito, Ecuador"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali","family":"Bhardwaj","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Missouri\u2013Kansas City, Kansas City, MO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidharth","family":"Misra","sequence":"additional","affiliation":[{"name":"Department of General Surgery, University of Texas Southwestern Medical Center, Dallas, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tejesh","family":"Bangalore Shivashankar","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Command Hospital Air Force, Bangalore, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramita","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Station Medicare Centre, Air Force Station Udhampur, Udhampur, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,4,26]]},"reference":[{"key":"e_1_3_3_2_2","unstructured":"GOLD 2025: Global Strategy for the Diagnosis Management and Prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease 2025. Accessed July 7 2025. https:\/\/goldcopd.org\/2025-gold-report\/"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.19.0397"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.154.4.8887592"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00162414"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.04.010"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1080\/15412555.2025.2449889"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201104-0597OC"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202201-0209PP"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0000000000000251"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2021.04.025"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60988-X"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(17)30125-X"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2016.07.010"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403290"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.2165\/11584340-000000000-00000"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S150656"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2018.00049"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2019.105819"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708208"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S294333"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2024.12.001"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2413181"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2500012"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(14)70001-3"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.06-0702"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0006-341X.2000.00455.x"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cegh.2023.101484"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1186\/s41747-020-0145-y"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202301-0106PP"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201108-1553OC"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S347948"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmii.2020.11.001"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.arbres.2025.07.017"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.4103\/sja.sja_501_25"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1080\/15412555.2025.2467657"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.3390\/diseases11040152"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2026.108983"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2024.2417184"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.04.020"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.2147\/JAA.S502216"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vhri.2022.12.007"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1080\/02770903.2020.1837158"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2025.2520701"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S343249"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280261437728","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280261437728","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280261437728","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:17:09Z","timestamp":1790763429000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280261437728"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,26]]},"references-count":47,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["10.1177\/10600280261437728"],"URL":"https:\/\/doi.org\/10.1177\/10600280261437728","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,26]]}}}